|Videos|April 14, 2023
Role of Circulating Tumor DNA Testing in Colorectal Cancer
In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.
Advertisement
Advertisement
Trending on OncLive
1
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
2
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
3
Early Discontinuation of Adjuvant Osimertinib Doubles Recurrence Risk in EGFR-Mutated NSCLC
4
Dr Spira on the Data Supporting the Phase 3 Development of Iza-Bren in EGFR-Mutant NSCLC
5